Reanalyzing a Randomized Controlled Trial of Invasive Aspergillosis Using a Desirability of Outcome Ranking Approach: Voriconazole Versus Amphotericin B Deoxycholate
- Journal
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Q1)
- Published
- 26 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Julio C Zuniga-Moya, Marcela Araujo de Oliveira Santana, Luis Ostrosky-Zeichner, George R Thompson, Thomas J Walsh, Andrej Spec
- PMID
- 42644615
- DOI
- 10.1093/cid/ciag457
Why clinicians should know about it
- Picked for Microbiology (medical) (top studies of the week, 30 August 2026): Reanalysis of aspergillosis RCT using DOOR, antifungal outcomes
Abstract
Efficacy of antifungal therapy in invasive aspergillosis relies primarily on mortality, overlooking critical measures of treatment response. We used the Mycoses Study Group Education & Research Consortium (MSG) Desirability of Outcome Ranking (DOOR) framework to assess efficacy of antifungal therapies by integrating mortality, treatment failure, and severe adverse events. Voriconazole achieved better overall outcomes than amphotericin B using the DOOR approach.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.